Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1321–1324. doi: 10.1128/aac.40.5.1321

Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

P J Wood 1, L L Ioannides-Demos 1, E B Bastone 1, W J Spicer 1, A J McLean 1
PMCID: PMC163321  PMID: 8723496

Abstract

Pseudomonas aeruginosa ATCC 27853 was exposed to tobramycin concentration-time profiles modelling in vivo bolus and infusion dosing. Dependence of bactericidal and bacteriostatic activity on the initial profile of peak concentration (bolus effect > infusion) and area under the antibiotic concentration-time curve was observed at peak concentration/MIC ratios of 10 or below.

Full Text

The Full Text of this article is available as a PDF (190.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barclay M. L., Begg E. J., Hickling K. G. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet. 1994 Jul;27(1):32–48. doi: 10.2165/00003088-199427010-00004. [DOI] [PubMed] [Google Scholar]
  2. Bastone E. B., Li S. C., Ioannides-Demos L. L., Spicer W. J., McLean A. J. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother. 1993 Apr;37(4):914–917. doi: 10.1128/aac.37.4.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beaubien A. R., Ormsby E., Bayne A., Carrier K., Crossfield G., Downes M., Henri R., Hodgen M. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother. 1991 Jun;35(6):1070–1074. doi: 10.1128/aac.35.6.1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gibson J., Johnson L., Snowdon L., Joshua D., Young G., MacLeod C., Sader C., Iland H., Vincent P., Kronenberg H. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol. 1993 Aug;58(1-2):63–72. [PubMed] [Google Scholar]
  5. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Henley C. M., 3rd, Schacht J. Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity. Audiology. 1988;27(3):137–146. doi: 10.3109/00206098809081584. [DOI] [PubMed] [Google Scholar]
  7. Ioannides-Demos L. L., Li S. C., Bastone E. B., Spelman D. W., Hooper R. E., Cousins V. C., McLean A. J. Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin. J Antimicrob Chemother. 1994 Aug;34(2):267–274. doi: 10.1093/jac/34.2.267. [DOI] [PubMed] [Google Scholar]
  8. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
  9. LeBel M., Spino M. Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet. 1988 Feb;14(2):71–95. doi: 10.2165/00003088-198814020-00002. [DOI] [PubMed] [Google Scholar]
  10. Li S. C., Bowes G., Ioannides-Demos L. L., Spicer W. J., Hooper R. E., Spelman D. W., Tong N., McLean A. J. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients. J Antimicrob Chemother. 1991 Oct;28(4):561–568. doi: 10.1093/jac/28.4.561. [DOI] [PubMed] [Google Scholar]
  11. McLean A. J., Bastone E. B., Ioannides-Demos L. L., Spicer W. J. Bactericidal effect of gentamicin trough concentration provides a rationale for administration of bolus doses and maintenance of trough levels. J Antimicrob Chemother. 1994 May;33(5):999–1004. doi: 10.1093/jac/33.5.999. [DOI] [PubMed] [Google Scholar]
  12. Mendelson J., Portnoy J., Dick V., Black M. Safety of the bolus administration of gentamicin. Antimicrob Agents Chemother. 1976 Apr;9(4):633–638. doi: 10.1128/aac.9.4.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pechère J. C., Craig W. A., Meunier F. Once daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother. 1991 May;27 (Suppl 100):149–152. doi: 10.1093/jac/27.suppl_c.149. [DOI] [PubMed] [Google Scholar]
  14. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  15. Prins J. M., Büller H. R., Kuijper E. J., Tange R. A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 Feb 6;341(8841):335–339. doi: 10.1016/0140-6736(93)90137-6. [DOI] [PubMed] [Google Scholar]
  16. Tran Ba Huy P., Bernard P., Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest. 1986 May;77(5):1492–1500. doi: 10.1172/JCI112463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tran Ba Huy P., Deffrennes D. Aminoglycoside binding sites in the inner ears of guinea pigs. Antimicrob Agents Chemother. 1988 Apr;32(4):467–472. doi: 10.1128/aac.32.4.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tran Ba Huy P., Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988 May-Jun;105(5-6):511–515. doi: 10.3109/00016488809119511. [DOI] [PubMed] [Google Scholar]
  19. Tulkens P. M. Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data. Scand J Infect Dis Suppl. 1990;74:249–257. [PubMed] [Google Scholar]
  20. Tulkens P. M. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother. 1991 May;27 (Suppl 100):49–61. doi: 10.1093/jac/27.suppl_c.49. [DOI] [PubMed] [Google Scholar]
  21. Verpooten G. A., Giuliano R. A., Verbist L., Eestermans G., De Broe M. E. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 Jan;45(1):22–27. doi: 10.1038/clpt.1989.4. [DOI] [PubMed] [Google Scholar]
  22. Vogelman B., Craig W. A. Kinetics of antimicrobial activity. J Pediatr. 1986 May;108(5 Pt 2):835–840. doi: 10.1016/s0022-3476(86)80754-5. [DOI] [PubMed] [Google Scholar]
  23. White C. A., Toothaker R. D., Smith A. L., Slattery J. T. In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli. Antimicrob Agents Chemother. 1989 Jul;33(7):1046–1051. doi: 10.1128/aac.33.7.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES